Browse studies

Find your next paid study

25,415 recruiting studies available now

INCLUSION - Enhancing PrEP Uptake and Retention Among Latine Transgender Women and Gay, Bisexual, and Other Men Who Have Sex With Men in the South Using Long-Acting Injectable PrEP

The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual…

HIV PreventionHIV Pre-exposure ProphylaxisHIV Prevention Program+2 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Duke UniversityNCT07218211

Phase 4

ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participant…

Solid Tumors

Estimated

~$25 – $1,500

Actual pay is set by the research site.

PfizerNCT05203172

Phase 3

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Nonfunctional Neuroendocrine Neoplasms (REMAIN Trial)

This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation …

Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Neoplasm

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Washington University School of MedicineNCT07842172

Phase 3

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but ha…

Alopecia Areata

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AbbVieNCT06012240

Observational

A Single-center Randomized Controlled Trial Evaluating Whether Adding Fundal Mucosal Ablation (FMA) to Standard Endoscopic Sleeve Gastroplasty (ESG) Leads to Greater Weight Loss, Improved Obesity-related Comorbidities, and Better Metabolic and Hormonal Outcomes Compared With ESG Alone in Adults With Obesity.

The ENLIGHT Trial is a single-center, randomized controlled trial evaluating whether adding fundal mucosal ablation (FMA) to endoscopic sleeve gastroplasty (ES…

ObesityObesity (Body Mass Index >30 kg/m2)

Estimated

~$10 – $750

Actual pay is set by the research site.

West Virginia UniversityNCT07792226

Phase 1

A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that …

Recurrent Small Cell Lung CancerExtensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer+6 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)

Phase 1

A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of p…

Adrenocortical Carcinoma (ACC)Recurrent Adrenocortical Carcinoma (ACC)Recurrent Abdominal Adrenocortical Carcinoma (ACC)+2 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06487481

Phase 1

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) gene transfer treatment for X-linked severe combined immunodeficien…

X-linked Severe Combined Immunodeficiency (XSCID)

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT01306019

Phase 4

Varenicline for Smoking Cessation in Pancreatitis: An Open-Label Trial

This study will look at how safe and how effective varenicline, a commonly used medication for smoking cessation, is in helping patients with pancreatitis stop…

PancreatitisChronic PancreatitisAcute Pancreatitis (AP)+1 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Mayo ClinicNCT07874841

Observational

A Prospective Multicenter Trial Evaluating the Safety and Effectiveness of Endo-SPONGE for the Treatment of Anastomotic or Hartmann's Stump Leakages in the Lower Pelvic Area

This study is intended to evaluate the safety and effectiveness of Sponge-based Endoscopic Vacuum Therapy (EVT) using Endo-SPONGE for the treatment of Anastomo…

Anastomotic LeaksHartmanns Stump Leakage

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Boston Scientific CorporationNCT07035431

Phase 2

A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may …

Advanced Colon AdenocarcinomaAdvanced Colorectal AdenocarcinomaAdvanced Rectal Adenocarcinoma+10 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Phase 2

A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)

This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, po…

Recurrent Multiple MyelomaRefractory Multiple Myeloma

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06948084